Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Standard Thoracic Radiotherapy
RADIATION
2 trials
Sponsors
National Taiwan University Hospital
, Merck Sharp & Dohme LLC
Conditions
Small Cell Lung Cancer
Small Cell Lung Cancer, Limited Stage
Stage III Non-small Cell Lung Cancer
Phase 3
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Active, not recruiting
NCT04624204
Merck Sharp & Dohme LLC
Small Cell Lung Cancer
Start: 2020-12-08
End: 2027-10-28
Target: 672
Updated: 2025-07-02
Unknown Phase
Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial
NCT03077854
National Taiwan University Hospital
Small Cell Lung Cancer, Limited Stage, Stage III Non-small Cell Lung Cancer
Start: 2016-06-30
End: 2023-05-31
Target: 64
Updated: 2019-03-11
Related Papers
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.
2024-02-01
Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer.
2022-04-29
11 citations
Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs. Concurrent Chemoradiation Therapy in Patients With Newly Diagnosed Limited-Stage Small-Cell Lung Cancer: KEYLYNK-013.
2021-11-01
KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC.
Journal of Clinical Oncology
2021-05-20
4 citations